Rectal adenocarcinoma

3 trials 1 recruiting MedDRA PT
3 Registered trials
1 Recruiting
2 Unique sponsors
6 Unique IMPs
0 Commercial trials
Drug classes (ATC)
— ATC code not specified 2
L Oncology (ATC L) 1
V Various (ATC V) 1
Mechanism of action (INN-stem analysis)
Antimetabolite 2 substances
Unknown / small molecule 1 substance
Supportive / rescue 1 substance
Topoisomerase I inhibitor 1 substance
Platinum compound 1 substance
Phase III: 2 Phase II: 1

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase III

2 trials
  • Institut Gustave Roussy Academic
    CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN HYDROCHLORIDE TRIHYDRATE; OXALIPLATIN
    2023-506885-30-00 1 country 2024 n=212
    Recruiting
  • Unicancer Academic
    IMP not specified
    2025-521619-37-00 1 country n=160
    Pending

Phase II

1 trial
  • Institut Gustave Roussy Academic
    HYDROGEN PEROXIDE
    2025-524378-40-00 1 country n=24
    Pending
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Institut Gustave Roussy Academic 2 Phase II, Phase III 1
Unicancer Academic 1 Phase III 0
New trials by year
2024
1
← All indication landscapes